Trials / Completed
CompletedNCT00549185
Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma
An Open-label Multi-dose-escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Every 3 Weeks in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to determine the maximum tolerated dose of SAR3419 and to characterize the dose limiting toxicity(ies). Secondary objectives are to determine the anti-lymphoma activity, the global safety and the PK profile.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAR3419 | Intravenous infusion |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2007-10-25
- Last updated
- 2012-02-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00549185. Inclusion in this directory is not an endorsement.